• Agency for Science, Technology and Research (A*STAR): A*STAR Peptide Engineering Programme (PEP) Technologies and Capability
  • Angelini S.p.A.: Design, Synthesis, and Optimization of Novel Dual Bacterial Topoisomerase Type IIA Inhibitors
  • AssayQuant Technologies, Inc.: CSox-Based Sensors for Continuous, Homogeneous and Quantitative Monitoring of Protein Kinase and Phosphatase Activity
  • BellBrook Labs: Targeting Cyclic GAMP Synthase for Interferon-Driven Autoimmune Diseases
  • BellBrook Labs: The Transcreener® ADP Assay: A Universal Kinase Assay for HTS and Lead Optimization
  • BIOCAD: Development of New Next-In-Class Selective BTK BCD-141 Series Inhibitors
  • Biodesy, Inc.: Identifying Allosteric Modulators of KRas Using Second Harmonic Generation
  • BioSolveIT, Inc.: Exploring 647,141,139 Molecules Available On Demand
  • Boryung Pharmaceticals Co. Ltd.: Identification of BR101459, the First Non-TZD PPAR? Full Agonist for the Treatment of Type 2 Diabetes and Its Diminishing Potential in Adverse Effect of TZDs
  • Boston University: Development and Validation of Macrocycle Specific Molecular Descriptors and Their Validation by Machine Learning
  • BPS Bioscience, Inc.: Methods for Drug Discovery Through Biochemical and Cell Based Assays for Immunotherapy Checkpoint Activators and Inhibitors
  • Bristol-Myers Squibb: 4-Aminopyrrolo[1,2-b]Pyridazine-3-Carboxamide as Janus Kinase (JAK) Inhibitors: Discovery of Potent Dual JAK1/JAK3 Inhibitors Using 3-Azabicyclo[3.3.0]Octane as 4-Amino Substituent
  • ChemBridge Corporation: Synthetic Macrocycle Library with Potential to Find Hits for CNS Drug Discovery Programs
  • ChemDiv, Inc.: Library of sp3-Enriched a-Helix and b-Turn Mimetics: Design and Synthesis
  • ChemPartner, Inc.: Parallel FBDD Approaches Targeting Nicotinamide Phospho-Ribosyl-Transferase (NAMPT)
  • China Pharmaceutical University: The New Plant Parinari kerstingii Engl.: Anti-Inflammatory Activities and Toxicity Study
  • Chinese Academy of Medical Sciences: Development of a Selective S1P1 Receptor Agonist, IMMH002, as a Potential Therapeutic Agent for Psoriasis
  • Chinese Academy of Medical Sciences: XH010, a Novel PI3K/mTOR Dual Inhibitor for Treatment of Human Cancers
  • Chinese Academy of Medical Sciences: STEAP3 Regulated Ion Iron Changes in Liver Cancer
  • Chinese Academy of Sciences: In-Depth Proteome Coverage by Improving Efficiency for Membrane Proteome Analysis
  • Chung-Ang University: Discovery of Reversible and Mutant Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  • Cresset: Deciphering Kinase SAR Using Electrostatics
  • Daegu Gyeongbuk Institute of Science and Technology (DGIST): Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) Using Molecular Dynamics Simulations
  • Damanhour University: Discovery of New Indomethacin-Based Analogs with Potentially Selective Cyclooxygenase-2 Inhibition and Observed Diminishing to PGE2 Activities
  • Dankook University: Molecular Dynamics Simulations of E2 Protein Cage
  • Domainex Ltd.: Fragment Screening Against the Lysine Methyltransferase G9a Using Microscale Thermophoresis
  • Edelris SAS: Towards the Discovery of BAY-850, a Selective and Cell-Active ATAD2 Bromodomain Inhibitor
  • Enamine Ltd.: Novel Specific Covalent Warheads for Fragment Library Synthesis: Functionalized Diazirines and Novel Amino Boronic Acids
  • Eurofins DiscoverX: Modifying Standard Assay for Assessing Allosteric Activity
  • Eurofins Pharma Discovery Services: Binding and Functional Analysis - Complementary Approaches in Safety Pharmacology
  • Ewha Womans University: Stepwise Structure-Based Virtual Screening for the Discovery of Protein-Protein Interaction Inhibitors of Ataxin-1 and Capicua
  • Fidelta Ltd.: Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction
  • Florida A&M University: Potential GPCR Ligands for Schizophrenia
  • GE Healthcare: Development of a Protein-Protein Interaction Inhibition Assay Using Biacore™ 8K
  • GE Healthcare: Why Sensitivity Matters: Reliable Hit Characterization for Challenging Targets Using High Sensitivity SPR Systems
  • GE Healthcare: Binding Kinetics by Surface Plasmon Resonance: Insight into Structure-Kinetics/Thermodynamics Relationships
  • Genomics Institute of the Novartis Research Foundation: Discovery of Encorafenib, a Potent, Selective RAF Kinase Inhibitor for Treatment of BRAFV600E-Positive Melanoma
  • Gyros Protein Technologies: Rapid Picomolar Affinity Measurements Using Gyrolab Automated Immunoassay Systems
  • Hypha Discovery Ltd.: Microbial Biotransformation as a Tool to Exploit the Potential of Drug Metabolites for Lead Optimization
  • Key Organics Ltd.: Building a Diverse and Experimentally-Curated Fragment Library
  • Key Organics Ltd.: New BIONET Compounds for CNS Diseases
  • Korea Institute of Science and Technology (KIST): Structure-Activity Relationships of Baulamycin A Derivatives
  • Korea Research Institute of Chemical Technology (KRICT): Design and Synthesis of DYRK1B Inhibitors
  • Life Chemicals, Inc.: Novel Fragments Libraries from Life Chemicals
  • Life Chemicals, Inc.: Small Molecule Libraries for Early Drug Discovery from Life Chemicals, Inc.
  • LifeArc: Fragment-Based Discovery of Inhibitors of the CSF1R:IL-34 Interaction Targeting Neuroinflammation in Alzheimer's Disease
  • Masaryk University: Selective Stabilization of G-Quadruplex Structures by Quaternary Benzophenantridine Alkaloids
  • Mayo Clinic: Assemblage of Parkin Conformational States Coupled with Fragment-Based Structure-Guided Drug Discovery for Novel Activators
  • Medical & Biological Laboratories, Co., Ltd.: Fluoppi: A Cell Based Assay Harnessing Intracellular Phase Transitions to Visualize Activities of Protein-Protein Interaction Modulators (PPIMs)
  • Merck Sharp & Dohme (MSD): Exploring Stapled Peptide Permeability Using p53 as a Model System
  • Nanyang Technological University: Structural Insights into Designing Selective ATP-Competitive Inhibitors of Vaccinia-Related Kinase 1 (VRK1), a Mitotic Protein Kinase
  • National Cancer Center: A Secondary RET Mutation in the Activation Loop Conferring Resistance to Vandetanib Through Allosteric Effects
  • Osaka Dental University: Searching for the Pharmaceutical use of PTH Receptor in Japanese Quail
  • Prestwick Chemical PC SAS: The Prestwick Drug-Fragment Library: An Innovative Tool for FBDD
  • Promega Corporation: Exploring Kinetic Selectivity for Kinase Inhibitors in Live Cells Using BRET
  • Promega Corporation: Quantitate Kinase Inhibitor Potency and Selectivity in Live Cells Using BRET
  • Promega Corporation: Monitoring Functional Mechanisms of Protein Degradation in Living Cells
  • Purdue University: Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors
  • Redshift BioAnalytics: Enhanced Protein Structural Characterization using Microfluidic Modulation Spectroscopy (MMS)
  • Rutgers, The State University of New Jersey: Structure-Based Discovery of Novel Sigma 1 Receptor Antagonists with Antinociceptive Efficacy in Rats
  • Sanford Burnham Prebys Medical Discovery Institute: Structural Basis for Potency of SMAC Mimetic Antagonists for Inhibitor of Apoptosis Protein ML-IAP
  • Seoul National University: A Cell Penetrating Peptide that Helps Deliver Cyclosporine A in a Nanomolar Concentration as a Component of a New Formulation for Dry Eye Syndrome Therapy
  • Singapore-MIT Alliance for Research and Technology (SMART) Centre: Targeting the Ribonucleome for Antibiotic Development
  • South Dakota State University: Development of a High-Performance Liquid Chromatography Method for the Analysis of Next-Generation Cyanide Antidotes, 3-Mercaptopyruvate in Plasma
  • Sungkyunkwan University: Site-Selective Chemical Conjugation onto Antibodies
  • Taros Chemicals GmbH & Co. KG: European Lead Factory - Collective Intelligence Boosting European Drug Discovery with Public Compound Collection
  • University of California, Riverside: Enthalpy-Based Screening and Enthalpy-Entropy Compensation Analysis for the Design of Potent and Selective IAPs Inhibitors
  • University of California, Riverside: Design, Synthesis and Evaluation of Novel, Potent Irreversible XIAP Inhibitors with Superior Cellular Activity in Refractory Tumors
  • University of California, San Diego: DYRK2, a Novel Therapeutic Target in 26S Proteasome Dependent Neoplastic Malignancies
  • University of California, Santa Cruz: CycLS: Accurate, Whole-Library Sequencing of Cyclic Peptides Using Tandem Mass Spectrometry
  • University of California, Santa Cruz: Membrane-Permeable Lariat Peptides
  • University of California, Santa Cruz: Improving Upon Nature: A Medicinal Chemistry Optimization of Cordyheptapeptide A and B
  • University of California, Santa Cruz: Synthetic Cyclic Peptomers as Virulence Blockers that Suppress Pathogenicity of Antibiotic Resistant Bacteria
  • University of Eastern Finland: Molecular Docking and Hydration Site Approaches in the Discovery of Cyclin G Associated Kinase of Inhibitors
  • University of Florida: The Evolution of Apratoxins: Total Synthesis of Natural Products and Analogues with Improved Anticancer Activity
  • University of Groningen: Drug Discovery at the Speed of Sound
  • University of Hong Kong: Discovering Small Compound Modulators for Secretin Receptor
  • University of Pittsburgh: Ubiquitin Carboxyl-Terminal Hydrolase-L5 Inhibitor Diminishes TGF?-1 Signaling and Ameliorates Pulmonary Fibrosis
  • University of South Africa: Synthesis, Cytotoxicity and Molecular Docking of the 4-Aminoquinazoline Appended Benzofuran Hybrids as Epidermal Growth Factor Receptor Inhibitors
  • University of Southern California: Structure-Based Design of Novel Non-Morphinan Bi-Functional Small Molecule Analgesics with Reduced Liabilities
  • University of Southern California: Structure Based Screening for P2Y2 Receptor Antagonists
  • University of Tokyo: Maturing a Macrocyclic Peptide into a Drug Candidate Using RaPID Scanning
  • University of Toronto: Overcoming the Blood Brain Barrier with Focused Ultrasound Therapy and Gold Nanoparticles
  • University of Washington: Saturation Mutagenesis Comprehensively Identifies Resistance Mutations to Conformation-Selective Kinase Inhibitors
  • Uppsala University: Target Engagement-Mediated Amplification (TEMA): Selective Monitoring of Drug-Target Interactions
  • Uppsala University: The Cellular Thermal Shift Assay (CETSA) with Readout by PEA - Sensitive Measurement of Cellular Drug-Protein Binding
  • Virginia Commonwealth University: Development of Mu Opioid Receptor Selective Modulators as Novel Therapeutics for Substance Abuse and Addiction
  • Weizmann Institute of Science: Quantitative Analysis of Protein-Protein Interactions In Vivo to Achieve Proteome Wide Information





Cambridge Healthtech Institute (CHI) 鼓励与会者透过海报展示发表他们的研究成果,以提升其自身知名度。意者请在2018年2月23日前提交摘要并全额缴付报名费,以保留海报板及在年会手册上登载摘要内容。



  • 可向制药大厂、生物科技企业、学术机构、政府机关等单位的主管干部发表您的研究成果。
  • 可以省下50美金。
  • 自动成为海报比赛的候选者(详情请参阅下列内容)。
  • 海报内容摘要将刊载于年会手册上。

•         请务必于规定期限内提交海报摘要。
•         将依下列基准评选出2名最佳海报得奖者。
•         奖金将于主研讨会最后一天(不包含论坛日程)4月5日(四)于展示会大厅颁赠。得奖者若不克出席则将邮寄奖金支票。

•         摘要的明确性
•         数据的创新度
•         对于创药的重要性

•         海报外观品质与排版陈列是否一目了然
•         海报口头说明的清楚度与魅力

2017 Poster Competition Winners

Dr. Simon Hurst, CEO of Sygnature Discovery, sponsor of 2017 poster competition, awarding the winners:

Bin Zhao, Vanderbilt University
Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 Inhibitors

Alix Boucharlat, Institut Pasteur
Hydrocarbon-Stapled Peptide Inhibitors of NEMO as Potential Anti-Inflammatory and Anti-Cancer Drugs


**Full time graduate students and PhD candidates qualify for the student rate. Students are encouraged to present a research poster and receive an additional $150 discount off their registration fee and will be recognized as a Student Fellow of the event.


  • Receive a poster presentation slot and a savings off your registration fee
  • Present your research poster to an international delegation representing leaders from top pharmaceutical, biotech, academic and government institutions
  • Meet face-to-face with potential employers and contacts to further your research and form collaborations
  • Be entered in the Poster Competition - with cash prizes!
  • Student Fellows must register and submit a poster abstract by February 23, 2018.








* CHI有权将海报主题与摘要刊登于会议行销数据与商品上并发行之。
** 每位报名人只能使用一次海报发表的优惠。